Lessons from multiple sclerosis: Models, concepts, observations

Annals of the Rheumatic Diseases

Volumn 67, Issue SUPPL. 3, 2008, Pages

  Wekerle, H ^a  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLATIRAMER; MYELIN; NATALIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNITY; B LYMPHOCYTE; CELL COMPOSITION; CELL INVASION; CELL LINEAGE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; ENCEPHALOMYELITIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATORY INFILTRATE; LEUKOENCEPHALOPATHY; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; NONHUMAN; PASSIVE TRANSPORT; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC ORGANISM;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTE SUBSETS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; T-LYMPHOCYTE SUBSETS;

EID: 56749169457     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.098020     Document Type: Conference Paper

References (59)

1. Milgrom F, Witebsky E. Autoantibodies and autoimmune disease. JAMA 1962;181:707-16.
2. Toyka KV, Drachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 1975;190:397-9.
3. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115-21.
4. Lassmann H, Wekerle H. The pathology of multiple sclerosis. In: Compston A. Confavreux C, Lassmann H, McDonald I, Miller D, Noseworthy J, et al, eds. McAlpine's multiple sclerosis. London, UK: Churchill Livingstone Elsevier, 2006:557-600.
5. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000;192:393-404.
6. Junker A, Ivanidze J, Malotka J, Eiglmeier I, Lassmann H, Wekerle H, et al. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 2007;130:2789-99.
7. Oksenberg JR, Panzara MA, Begovich AB, Mitchell D, Erlich HA, Murray RS, et al. Selection for T-cell receptor Vb-Db-Jb gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 1993;362:68-70.
8. Genain CP, Lee-Parritz D, Nguyen MH, Massacesi L, Joshi N, Ferrante R, et al. In healthy primates, circulating autoreactive T cells mediate autoimmune disease. J Clin Invest 1994;94:1339-45.
9. Meinl E, Hoch RM, Dornmair K, De Waal Malefijt R, Bontrop RE, Jonker M, et al. Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. Am J Pathol 1997;150:445-453.
10. Madsen LS, Andersson EC, Jansson L, Krogsgaard M, Andersen CB, Engsberg J, et al. A humanized model for multiple sclerosis using HLA DR2 and a human T cell receptor. Nat Genet 1999;23:343-7.
11. Ellmerich S, Mycko M, Takács K, Waldner H, Wahid FN, Boyton RJ, et al. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J Immunol 2005;174:1938-46.
12. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-74.
13. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-5.
14. O'Connor KC, Appel H, Bregoli L, Call ME, Catz I, Chan JA, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005;175:1974-82.
15. Kolln J, Ren HM, Da RR, Zhang YP, Spillner E, Olek M, et al. Triosephosphate isomerase- and glyceraldehyde-3-phosphate dehydrogenase-reactive autoantibodies in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol 2006;177:5652-8.
16. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007;204:2363-72.
17. Obermeier B, Mentele R, Malotka J, Kellermann J, Wekerle H, Lottspeich F, et al. Matching of oligoclonal Ig transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 2008;14:688-93.
18. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, et al. Induction of a non-encephalitogenic Th2 autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase II trial. Nat Med 2000:1176-1182.
19. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-75.
20. Coles AJ, Wing MG, Molyneux PD, Paolillo A, Davie CM, Hale G, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304.
21. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
22. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
23. Keegan M, König F, McClelland R, Brück W, Morales Y, Bitsch A, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579-82.
24. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88.
25. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998;8:681-94.
26. Wekerle H, Lassmann H. The immunology of inflammatory demyelinating disease. In: Compston A, Confavreux C, Lassmann H, McDonald I, Miller D, Noseworthy J, et al, eds. McAlpine's multiple sclerosis. London, UK: Churchill Livingstone Elsevier, 2006:491-546.
27. Wekerle H, Bradl M, Linington C, Kääb G, Kojima K. The shaping of the brain-specific T lymphocyte repertoire in the thymus. Immunol Rev 1996;149:231-43.
28. b mice: fine specificity and T cell receptor Vb expression of encephalitogenic T cells. Eur J Immunol 1995;25:1951-9.
29. Swanberg M, Lidman O, Padykov L, Eriksson P, Åkesson E, Jagodic M, et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005;37:486-94.
30. 't Hart BA, Van Meurs M, Brok HPM, Massacesi L, Bauer J, Boon L, et al. A new primate model for multiple sclerosis in the common marmoset. Immunol Today 2000;21:290-7.
31. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-8.
32. Bettelli E, Kuchroo VK. IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together. J Exp Med 2005;201:169-71.
33. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by TH1 and TH17. Nat Med 2008;14:337-42.
34. Wekerle H. Breaking ignorance: the case of the brain. In: Radbruch A, Lipsky PE, eds. Current concepts in autoimmunity and chronic inflammation. Berlin: Springer, 2006:25-50.
35. + T cells in a model for multiple sclerosis. J Exp Med 2001;194:669-76.
36. + T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001;166:7579-87
37. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993;72:551-60.
38. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 2006;116:2385-92.
39. Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 2006;116:2393-402.
40. Friese MA, Montalban X, Willcox N, Bell JI, Martin R, Fugger L. The value of animal models for drug development in multiple sclerosis. Brain 2006;129:1940-52.
41. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-8.
42. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76
43. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001;56:702-6.
44. Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004;127:1370-8.
45. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007;13:935-43.
46. Yednock TA, Cannon C, Fritz LC, Sánchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against a4b1 integrin. Nature 1992;356:63-6.
47. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GPA, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
48. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-9.
49. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30:694-700.
50. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. Control of established allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF-receptor-immunoglobulin fusion proteins. Eur J Immunol 1994;24:2040-8.
51. Körner H, Goodsall AL, Lemckert FA, Scallon BJ, Ghrayeb J, Ford AL, et al. Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1995;92:11066-70.
52. Klinkert WEF, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H. TNF-α receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 1997;72:163-8.
53. Feldmann M, Maini RN. Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
54. The Lenercept MS Study Group, The UBC MS/MRI Analysis Group. TNF neutralization in MS. Results of a randomized placebo controlled multicenter trial. Neurology 1999;53:457-65.
55. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-62.
56. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-87.
57. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 2004;101(Suppl 2):14599-606.
58. H4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998;43:236-43.
59. H genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998;102:1045-50.